Abstract
In an article written by B. Fisher (1984), the following statement can be found: “Competing forces have continuously played a role in determining the management of breast cancer.” This statement should remind research physicians that innovative treatment programs will meet with numerous obstacles at all levels before their achievements can be considered as establishing new paradigms. In fact, most clinicians dealing with research are mainly interested in expanding routine science which flourishes as long as the old paradigms remain the standard that governs clinical activity (Fisher 1992).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bonadonna G (1992) Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 52: 2127–2137
Bonadonna G, Beretta G, Tancini G et al. (1975) Adriamycin studies at the Istituto Nazionale Tumori, Milan. Cancer Chemother Rep 6: 231–245
Bonadonna G, Gianni L, Santoro A et al. (1993) Drugs ten years later: epirubicin. Ann Oncol 4: 359–369
Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C (1995a) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332: 901–906
Bonadonna G, Zambetti M, Valagussa P (1995b) Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 273: 542–547
Bonadonna G, Valagussa P, Zucali R, Salvadori B (1995c) Primary chemotherapy in surgically resectable breast cancer. CA 45: 227–243
Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal cytotoxic, or immune therapy: 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 399:1–15, 71–85
Fisher B (1984) The role of science in the evolution of breast cancer management. Heat Memorial Award Lecture. In: Ames FC, Blumenschein GR, Montague ED (eds) Current controversies in breast cancer. University of Texas Press, Austin, pp 1–21
Fisher B (1992) The evolution of paradigms for the management of breast cancer: a personal perspective. Cancer Res 52: 2371–2383
Gasparini G, Pozza F, Harris AL (1993) Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85: 1206–1219
Gianni AM, Siena S, Bregni M et al. (1995) 5-year results of high-dose sequential (HDS) adjuvant chemotherapy in breast cancer with ≥10 positive nodes. Proc Am Soc Clin Oncol 14: 90
Gianni L, Straneo M, Capri G, Villani F, Munzone E, Bonadonna G (1994) Optimal dose and sequence finding study of paclitaxel (P) by 3 h infusion combined with bolus doxorubicin ( D) in untreated metastatic breast cancer patients. Proc Am Soc Clin Oncol 13: 74
Henderson IC (1994) Adjuvant systemic therapy for early breast cancer. Cancer 74: 401–409
Valagussa P, Moliterni A, Terenziani M, Zambetti M, Bonadonna G (1994a) Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer. Ann Oncol 5: 803–808
Valagussa P, Zambetti M, Biasi S, Moliterni A, Bonadonna G (1994b) Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer. Ann Oncol 5: 209–216
Wood WC, Budman DR, Korzun AH et al. (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330: 1253–1259
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Bonadonna, G. (1996). Future Developments in Adjuvant Systemic Therapy for High-Risk Breast Cancer. In: Senn, H.J., Gelber, R.D., Goldhirsch, A., Thürlimann, B. (eds) Adjuvant Therapy of Breast Cancer V. Recent Results in Cancer Research, vol 140. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79278-6_25
Download citation
DOI: https://doi.org/10.1007/978-3-642-79278-6_25
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-79280-9
Online ISBN: 978-3-642-79278-6
eBook Packages: Springer Book Archive